Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients

American Journal of Hematology

Volumn 83, Issue 9, 2008, Pages 717-720

  Baronciani, Donatella ^a   Rambaldi, Alessandro ^b   Iori, Anna Paola ^c   Di Bartolomeo, Paolo ^d   Pilo, Federica ^a   Pettinau, Martina ^a   Depau, Cristina ^a   Mico, Caterina ^b   Santarone, Stella ^d   Angelucci, Emanuele ^a  

^a Ospedale Oncologico A Businco   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Ospedale Civile di Pescara   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; FLUDARABINE PHOSPHATE; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; SKIN TOXICITY;

ADOLESCENT; ADULT; AGED; BUSULFAN; COMBINED MODALITY THERAPY; COMORBIDITY; DIGESTIVE SYSTEM DISEASES; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, TOXIC; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; REOPERATION; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 51449098971     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21240     Document Type: Article

References (20)

1. Slavin S, Nagler A, Najarstak E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease. Blood 1998;91:756-763.
2. Baron F, Maris MB, Sandmaier BM, et al. Graft versus tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23:1993-2003.
3. Storb R, Yu C, Wagner JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048-3054.
4. Falda M, Busca A, Baldi I, et al. for the Gruppo Italiano Trapianto Midollo Osseo (GITMO) Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007;82:863-866.
5. Flynn CM, Hirsch B, Defor T, et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. Am J Hematol 2007;82:867-872.
6. Hogan WJ, Maris M, Storer B. Hepatic injury after non-myeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004;103:78-84.
7. Mohty M, Bay JO, Faucher C, et al. GvHD following allogeneic transplantation from HLA identical sibling with antitymocyte globulin based reduced intensity preparative regimen. Blood 2003;102:470-476.
8. Schmidt-Hieber M, Blau IW, Trenschel R, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2007;39:289-396.
9. Koenigsmann M, Mohren M, Jentsch-Ullrich K, et al. High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. Bone Marrow Transplant 2004;34:477-483.
10. Casper J, Knauf W, Kiefer T, et al. Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004;103:725-731.
11. Beelen DW, Trenschel R, Casper J, et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2005;35:233-241.
12. Shimoni A, Hardan I, Shem-Tov N, et al. Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007;48:2352-2359.
13. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplant (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. From the Fred Hutchinson Cancer Research Center. Blood. 2005;106:2912-2919.
14. Saito AM, Kami M, Mori S, et al. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Am J Hematol 2007;82:873-880.
15. Bitan M, Or R, Shapira MY, Resnick IB, et al. Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia. Bone Marrow Transplant 2008;41:69-78.
16. Uzunel M, Remberger M, Sairafi D, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation 2006;82:913-919.
17. Niederwieser D, Lange T, Cross M, et al. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol 2006;19:825-838.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-828.
19. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. Biol Blood Marrow Transplant 2003;9:215-233.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.